A custom collaboration with: Quintiles



Mike May is the editorial director of Pathways and a science writer who frequently covers biotechnology, healthcare and life-science technology.

Mike brings a broad scientific background to this work, including an M.S. in biological engineering from the University of Connecticut and a Ph.D. in neurobiology and behavior from Cornell University. He started his career in science writing and editing in 1991 as an associate editor at American Scientist, where he worked for seven years. Mike is the editorial director of Scientific American Worldview, the global biotechnology publication, and a frequent contributor to Nature Biotechnology.

John Rennie is a science writer and contributing editor to SCIENTIFIC AMERICAN who served as the editor in chief of the magazine between 1994 and 2009. During his tenure the magazine twice won National Magazine Awards for editorial excellence with the single-topic issues What You Need to Know about Cancer (Sept. 1996) and A Matter of Time (Sept. 2002).

In 2000 Rennie was the recipient of the Sagan Award for Public Understanding of Science, bestowed by the Council of Scientific Society Presidents. In Sept. 2003 the Potomac Institute for Policy Studies honored him with its Navigator Award for distinguished service in support of national science and technology policy. He serves as a trustee of the James Randi Educational Foundation. Rennie is also frequent commentator on scientific matters for television and radio.

Dr. Barry Bloom is Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health at Harvard University. He is a leading scientist in the areas of infectious diseases, vaccines, and global health and former consultant to the White House. He has been extensively involved with the World Health Organization (WHO) for more than 40 years. He is currently Chair of the Technical and Research Advisory Committee to the Global Programme on Malaria at WHO and has been a member of the WHO Advisory Committee on Health Research and chaired the WHO Committees on Leprosy Research and Tuberculosis Research, and the Scientific and Technical Advisory Committee of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.

After finding out that his brother, Stephen, had the terminal illness ALS, Jamie Haywood founded the ALS Therapy Development Institute in 1999. ALS TDI is the world’s first non-profit biotechnology company and accelerated research on the disease by hiring scientists to develop treatments outside of academia and for-profit corporations. They were the first to publish research on the safety of using stem cells in ALS patients.

In 2005 Jamie and his youngest brother Ben, along with close friend Jeff Cole, built PatientsLikeMe.com to give patients control and access to their healthcare information and compare it to others like them. Its bold (and somewhat controversial) approach involves aggregating users health info in order to test the effects of particular treatments, bypassing clinical trials. It was named one of “15 companies that will change the world” by CNN Money.

Jennifer Levin Carter is founder and president of N-of-One and a board certified internist. She completed her internship, residency and was chief resident at Mount Auburn Hospital in Cambridge, MA. Dr. Carter practiced internal medicine at Mount Auburn Hospital until 1996. Since 2000, Dr. Carter has been a healthcare analyst in biotechnology and medical technology. She has been a member of an angel group looking at early stage investment opportunities in healthcare. In 2000-2001, Dr. Carter consulted for a biodegradable polymer start-up company, on product development. She was the Medical Advisor to a PBS series on complementary medicine. Dr. Carter graduated Phi Beta Kappa, summa cum laude with Distinction in Molecular Biochemistry and Biophysics from Yale University. She received an MD from Harvard Medical School, where she was president of her class, and an MPH from The Harvard School of Public Health.

Since joining the Harvard faculty in 1969, Marc Roberts has taught economics, statistics, ethics, management, environmental policy and health policy in the Economics Department, the Kennedy School, the Law School and for the last 30 years, at the School of Public Health. In recent years he has played a leading role in the World Bank’s training efforts on health sector reform around the world—having taught courses and seminars for senior government leaders in nearly thirty countries—and on every continent except Antarctica.

Bernard Munos is an advisor in corporate strategy at Eli Lilly and Company, where he focuses on breakthrough innovation, open-source R&D, and the radical redesign of the pharmaceutical business model. He received his MBA from Stanford University, and holds other graduate degrees in economics and animal science from the University of California at Davis, and the Institut National Agronomique in Paris, France.

Dr. Schadt is the chief scientific officer for Pacific Biosciences and oversees the scientific strategy for the company, including creating the vision for next-generation applications of the company’s technology, contributing to the evolution of Pacific Biosciences’ transformative sequencing technology, and playing a key role in the company’s strategic relationships. He is also a founding member of Sage Bionetworks- an open access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models.

Dr. Schadt has contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes and obesity, which have been widely published in leading scientific journals. His research has provided novel insights into what is needed to master diverse, large-scale data collected on normal and disease populations in order to elucidate the complexity of disease and make more informed decisions in the drug discovery arena. Prior to joining Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience.

G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 40 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset (NASDAQ: VRUS), BioImagene and NewBridge, and is a member of the Boards of Directors of Catalyst Biosciences, CrossCart, DepoMed (NASDAQ: DEPO), Ikano Therapeutics, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx. Prior to founding Burrill & Company,where he is CEO, he spent 28 years with Ernst & Young, directing and coordinating the firm’s services to clients in the biotechnology/life sciences/high technology/manufacturing industries worldwide. In 2002, Mr. Burrill was recognized as the biotech investment visionary by Scientific American magazine (The Scientific American 50), and in 2008, he received the BayBio Pantheon 2008 DiNA lifetime achievement award for his worldwide biotech leadership.

PrintShare  |
  • email
  • LinkedIn
  • del.icio.us
  • Digg
  • Facebook
  • Twitter